Jefferies resumed coverage on VBI Vaccines with a new price target
$VBIV
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies resumed coverage of VBI Vaccines with a rating of Buy and set a new price target of $6.00 from $7.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/11/2022 | $5.00 → $2.00 | Strong Buy → Outperform | Raymond James |
| 3/8/2022 | $9.00 → $6.00 | Strong Buy | Raymond James |
| 12/29/2021 | $7.00 → $6.00 | Buy | Jefferies |
Raymond James downgraded VBI Vaccines from Strong Buy to Outperform and set a new price target of $2.00 from $5.00 previously
Raymond James reiterated coverage of VBI Vaccines with a rating of Strong Buy and set a new price target of $6.00 from $9.00 previously
Jefferies resumed coverage of VBI Vaccines with a rating of Buy and set a new price target of $6.00 from $7.00 previously
4 - VBI Vaccines Inc/BC (0000764195) (Issuer)
4 - VBI Vaccines Inc/BC (0000764195) (Issuer)
4 - VBI Vaccines Inc/BC (0000764195) (Issuer)